Cardiovascular complications are a major problem in chronic renal failure. We examined the effects of plasma calcium, phosphate, parathyroid hormone (PTH), and calcitriol on cardiac morphology in 5/6 nephrectomized rats. Fifteen weeks after nephrectomy rats were given a control diet, high-calcium or -phosphorus diet, or given paricalcitol treatment for 12 weeks. Sham-operated rats were on a control diet. Blood pressure, plasma phosphate, and PTH were increased, while the creatinine clearance was reduced in remnant kidney rats. Phosphate and PTH were further elevated by the high-phosphate diet but suppressed by the high-calcium diet, while paricalcitol reduced PTH without influencing phosphate or calcium. The high-calcium diet increased, whi...
Despite its benefits, the clinical use of cyclosporine A (CsA) is limited by its nephrotoxic propert...
Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats wit...
Vitamin D derivatives and calcimimetics are used to treat secondary hyperparathyroidism in patients ...
Cardiovascular complications are a major problem in chronic renal failure. We examined the effects o...
Hyperphosphatemia is a driving force in the pathogenesis of vascular calcification (VC) and secondar...
Secondary hyperparathyroidism is a systemic disorder that associates with bone and cardiovascular di...
Background. Chronic kidney disease (CKD) is associated with elevations in serum phosphate, calcium-p...
Background. Chronic kidney disease (CKD) is associated with elevations in serum phosphate, calcium-p...
Cardiovascular (CV) morbidity and mortality are significantly higher in patients with chronic kidney...
Peritoneal dialysis (PD) is associated with structural and functional alterations of the peritoneal ...
Cardiovascular (CV) morbidity and mortality are significantly higher in patients with chronic kidney...
Severe alterations of Cacium-Phospate metabolism are frequently associated with chronic kidney disea...
Secondary hyperparathyroidism is a systemic disorder that associates with bone and cardiovascular di...
Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyro...
Compensatory renal growth: modulation by calcium and 1,25-(OH)2D3. To further elucidate the mechanis...
Despite its benefits, the clinical use of cyclosporine A (CsA) is limited by its nephrotoxic propert...
Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats wit...
Vitamin D derivatives and calcimimetics are used to treat secondary hyperparathyroidism in patients ...
Cardiovascular complications are a major problem in chronic renal failure. We examined the effects o...
Hyperphosphatemia is a driving force in the pathogenesis of vascular calcification (VC) and secondar...
Secondary hyperparathyroidism is a systemic disorder that associates with bone and cardiovascular di...
Background. Chronic kidney disease (CKD) is associated with elevations in serum phosphate, calcium-p...
Background. Chronic kidney disease (CKD) is associated with elevations in serum phosphate, calcium-p...
Cardiovascular (CV) morbidity and mortality are significantly higher in patients with chronic kidney...
Peritoneal dialysis (PD) is associated with structural and functional alterations of the peritoneal ...
Cardiovascular (CV) morbidity and mortality are significantly higher in patients with chronic kidney...
Severe alterations of Cacium-Phospate metabolism are frequently associated with chronic kidney disea...
Secondary hyperparathyroidism is a systemic disorder that associates with bone and cardiovascular di...
Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyro...
Compensatory renal growth: modulation by calcium and 1,25-(OH)2D3. To further elucidate the mechanis...
Despite its benefits, the clinical use of cyclosporine A (CsA) is limited by its nephrotoxic propert...
Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats wit...
Vitamin D derivatives and calcimimetics are used to treat secondary hyperparathyroidism in patients ...